BRAF and differentiated thyroid carcinoma: Additionally, preliminary results from the phase III DECISION trial demonstrate that Sorafenib, a non-specific active BRAF inhibitor, significantly improves PFS compared to placebo in patients with progressive RAI-refractory differentiated thyroid carcinoma 40.